Posts Tagged ‘EASD’

Amycretin: Obesity Buzz of the Day at EASD

September 12, 2024 — The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]

Did Tirzepatide Steal the Show at EASD?

October 6, 2023 — At EASD this week, it was quite a showing for tirzepatide. Sold under the brand name Mounjaro, it’s already available for treating diabetes and it’s awaiting approval for treating obesity. Based on the research presented at EASD this week, semaglutide might be looking a little like old news. For tirzepatide, a total of 11 presentations […]